Showing results (111-120 of 170) with videos related to

Sort By:
Pageof 17
Progress in Clinical and Biological Research|January 1, 1990
Elutriation of bone marrow delineates two distinct natural suppressor cell populationsS J Noga, A C Fischer, L R Horwitz, et al.
Journal of Leukocyte Biology|March 1, 1988
Characterization of the natural suppressor cell population in adult rat bone marrowS J Noga, J E Wagner, L R Horwitz, et al.
American Journal of Veterinary Research|January 1, 1990
Naturally acquired enteric adenovirus infection in Syrian hamsters (Mesocricetus auratus)S V Gibson, A A Rottinghaus, J E Wagner, et al.
Blood|November 11, 1992
Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalationA M Yeager, J E Wagner, M L Graham, et al.
Bone Marrow Transplantation|September 9, 2008
Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survivalM J Burke, B Trotz, X Luo, et al.
The New England Journal of Medicine|June 22, 2000
Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell SourcesV Rocha, J E Wagner, K A Sobocinski, et al.
Blood Cells, Molecules & Diseases|March 28, 1998
Expression of alpha IIb beta 3 integrin (GPIIb-IIIa) in myeloid cell lines and normal CD34+/CD33+ bone marrow cellsC D Wall, P B Conley, J Armendariz-Borunda, et al.
Psychopharmacology|April 11, 1979
Every-other-day acetylmethadol disturbs circadian cycles of human motilityT J Crowley, R H Jones, M J Hydinger-Macdonald, et al.
Bone Marrow Transplantation|September 23, 2014
The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AMLP Hagen, J E Wagner, T E DeFor, et al.
Bone Marrow Transplantation|February 11, 2009
Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patientsM J Burke, B Trotz, X Luo, et al.
Pageof 17